# CheckMate 651 (NCT02741570)

> Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02741570
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Head and Neck Cancer
- Interventions: Nivolumab; Ipilimumab; Cetuximab/Erbitux; Cisplatin/Platinol; Carboplatin/Paraplatin; Fluorouracil/Adrucil
- Enrollment: 947
- Primary outcome: Overall Survival (OS) in Participants With Programmed Death-Ligand 1 (PD-L1) With a Combined Positive Score (CPS) ≥20
- Primary outcome: Overall Survival (OS) in All Randomized Participants

## Commentary we found

- YouTube: 2
- Podcasts: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=checkmate-651-nct02741570